Sorafenib plus low-dose cisplatin and fluorouracil hepatic arterial infusion chemotherapy versus sorafenib alone in patients with advanced hepatocellular carcinoma (SILIUS): a randomised, open label, phase 3 trial
Year: 2018
Type: article
Study designs: Randomized Controlled Trial, Clinical Trial
Authors: Masatoshi Kudo, Kazuomi Ueshima, Osamu Yokosuka, Sadahisa Ogasawara, Shuntaro Obi, Namiki Izumi, Hiroshi Aikata, Hiroaki Nagano, Etsuro Hatano, Yutaka Sasaki, Keisuke Hino, Takashi Kumada, Kazuhide Yamamoto, Yasuharu Imai, Shouta Iwadou, Chikara Ogawa, Takuji Okusaka, Fumihiko Kanai, Kohei Akazawa, Ken-ichi Yoshimura, Philip Johnson, Yasuaki Arai
Institutions: Kindai University, Chiba University, Musashino Red Cross Hospital, Hiroshima University Hospital, The University of Osaka, Kyoto University, Kumamoto University, Kawasaki Medical School, Ogaki Municipal Hospital, Okayama University, Ikeda Municipal Hospital, Takamatsu Red Cross Hospital, National Cancer Center Hospital, Niigata University, Kanazawa University, University of Liverpool
Language: English
Subfield: Hepatology
Field: Medicine
Domain: Health Sciences
Keywords: sorafenib, hepatic arterial infusion chemotherapy, cisplatin, 5-fluorouracil, advanced hepatocellular carcinoma, unresectable liver cancer, overall survival, combination chemotherapy, systemic therapy, liver metastasis, progression-free survival, liver function decline, quality of life, patient-reported outcomes, treatment-related adverse events
Open Access status: green
Awards: Analysis of metabolic reprogramming induced by cellular environment and its application to control hepato-carcinogenesis, Investigation of hepatocarcinogenic mechanisms by comprehensive ahalysis of cellular signaling responding to oxidative stress, Effect of tyrosine kinase inhibitor for immunological microenviroment of hepatocellular carcinoma, Alternative methods of evaluating treatment effect in case of correlated competing risks in clinical trials
OpenAlex ID: W2795708663
